bioXXmed AG (HAM:T5O) Other Financing: €0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:T5O bioXXmed AG HAM:T5O
33 GF Score
Price €0.77
GF Value €9.07
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is bioXXmed AG Other Financing?

bioXXmed AG HAM:T5O 33 Other Financing is €0.00 Mil as of Dec. 2025. GuruFocus rates HAM:T5O with a GF Score™ of 33/100 and a GF Value™ of €9.07 (Possible Value Trap). The stock has 3 warning signs investors should review.

bioXXmed AG's Other Financing for the six months ended in Dec. 2025 was €0.00 Mil.

bioXXmed AG's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

bioXXmed AG Other Financing Historical Data

* Premium members only.

The historical data trend for bioXXmed AG's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

bioXXmed AG Other Financing Chart

bioXXmed AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.04 0.00 0.00 0.00

bioXXmed AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HAM:T5O
33GF Score
bioXXmed AG HAM:T5O
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

bioXXmed AG Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €0.00 Mil mean?
bioXXmed AG (HAM:T5O) has a Other Financing of €0.00 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for bioXXmed AG and its competitors.
Is bioXXmed AG's Other Financing too high?
bioXXmed AG's current Other Financing is €0.00 Mil. Overall, bioXXmed AG has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioXXmed AG's Other Financing compare to VRTX and REGN?
bioXXmed AG's Other Financing of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for bioXXmed AG and its competitors. bioXXmed AG's current Other Financing is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioXXmed AG stock overvalued right now?
Based on GuruFocus' analysis, bioXXmed AG (HAM:T5O) is currently considered Possible Value Trap. The stock's GF Value™ is €9.07, compared to a current price of €0.77 — trading 91.5% below its estimated fair value. The current Other Financing is €0.00 Mil. bioXXmed AG's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For bioXXmed AG (HAM:T5O), the current Other Financing is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is bioXXmed AG (HAM:T5O) Overvalued in 2026?

Based on GuruFocus' analysis, bioXXmed AG stock appears to be undervalued. The current stock price of €0.77 is trading 91.5% below its estimated GF Value™ of €9.07. GuruFocus considers bioXXmed AG to be Possible Value Trap.

Key valuation signals for HAM:T5O:

  • Other Financing: €0.00 Mil
  • GF Value™: €9.07 vs. price of €0.77 (91.5% below fair value)
  • GF Score™: 33/100 with 3 warning signs

No single metric tells the full story. See the HAM:T5O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

bioXXmed AG Business Description

Other Exchanges T5O:Germany
Address Riedstrasse 2, Darmstadt, HE, DEU, 64295
bioXXmed AG is an investment and holding company in the technology sector. It originated from CytoTools GmbH, a successful German technology enterprise from the pharmaceuticals and medical products field.
33GF Score

Get the complete analysis for HAM:T5O

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price
€9.07
GF Value